Cocrystal Pharma Inc (FRA:8CC)
€ 1.99 0 (0%) Market Cap: 26.24 Mil Enterprise Value: 15.55 Mil PE Ratio: 0 PB Ratio: 2.15 GF Score: 61/100

Cocrystal Pharma Inc Q4 Investor Summit Transcript

Nov 14, 2022 / 04:30PM GMT
Release Date Price: €2.88 (+2.50%)
Unidentified Participant

(multiple speakers) Good morning, I would like to introduce James Martin, the Co-CFO and CEO (sic - Interim Co-CEO and CFO) of Cocrystal.

James Martin
Cocrystal Pharma, Inc. - Interim Co-CEO and CFO

Hello everyone. Thank you for attending the investor conference and your interest in Cocrystal Pharma. If you guys are ready, I'll get started here. Cocrystal as a NASDAQ listed company under the ticker symbol COCP. Start off with forward-looking statements. I encourage you to read them and also you can check out our filings on the sec.gov.

So what does Cocrystal do? Cocrystal is an antiviral company. And the space we're in is for therapeutics, primarily in influenza, COVID, norovirus and hepatitis C. We use a highly conserved region of these viruses in which we attach our molecules, and I'll get more into that in a minute. But all of this is driven by a proprietary drug discovery platform.

So investment highlights at Cocrystal are summarized as we target large global markets. These are influenza, COVID. These are both acute and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot